



**THE PENDING CLAIMS**


This listing of claims replaces all prior versions of claims in the application:

Claims 1-37 (Canceled)


38. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a single composition, wherein this composition comprises:

(A) a sole active component, which is a 1-hydroxy-2-pyridone of formula I or a pharmaceutically acceptable salt thereof:

where  $R^1$ ,  $R^2$ , and  $R^3$ , which are identical or different, are H or alkyl having 1 to 4 carbon



atoms, and  $R^4$  is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

- X is S or O;
- Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;
- Z is a single bond, or  
a linking radical comprising  
(1) O, or

(2) S, or

(3)  $-\text{CR}_2-$ , where R is H or  $(\text{C}_1-\text{C}_4)$ -alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain, which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, and

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H,  $(\text{C}_1-\text{C}_4)$ -alkyl, or a mixture thereof;

and


Ar is an aromatic ring system having one or two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy,  $(\text{C}_1-\text{C}_4)$ -alkyl, trifluoromethyl, and trifluoromethoxy; and

(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and


wherein the composition has a pH ranging from about 4.5 to about 6.5.

39. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a single composition, wherein this composition comprises:

(A) a sole active component, which is a 1-hydroxy-2-pyridone of formula I or a pharmaceutically acceptable salt thereof:



where  $R^1$ ,  $R^2$ , and  $R^3$ , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and  $R^4$  is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

- X is S or O;
- Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;
- Z is a single bond, or  
a linking radical comprising
  - (1) O, or
  - (2) S, or
  - (3)  $-CR_2-$ , where R is H or  $(C_1-C_4)$ -alkyl, or
  - (4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain, which optionally further comprises one or more of the following:
    - (i) a carbon-carbon double bond, and
    - (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, trifluoromethyl, and trifluoromethoxy, and wherein Ar is a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether; and

(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

40. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 38 in which the at least one 1-hydroxy-2-pyridone of formula I has a cyclohexyl radical in the R<sup>4</sup> position.

41. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 38 in which the at least one 1-hydroxy-2-pyridone of formula I has an octyl radical of the formula -CH<sub>2</sub>-CH(CH<sub>3</sub>)-CH<sub>2</sub>-C(CH<sub>3</sub>)<sub>3</sub> in the R<sup>4</sup> position.

42. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 38 in which the sole active component is 1-hydroxy-4-methyl-6-(4-(4-chlorophenoxy)phenoxy)methyl)-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the foregoing.

Claims 43-47 (Canceled)

48. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 38 in which the composition further comprises at least one additional surfactant chosen from anionic, cationic, nonionic, and amphoteric surfactants.

Claims 49-60 (Canceled)

61. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 39 in which the at least one 1-hydroxy-2-pyridone of formula I has a cyclohexyl radical in the R<sup>4</sup> position.

62. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 39 in which the at least one 1-hydroxy-2-pyridone of formula I has an octyl radical of the formula -CH<sub>2</sub>-CH(CH<sub>3</sub>)-CH<sub>2</sub>-C(CH<sub>3</sub>)<sub>3</sub> in the R<sup>4</sup> position.

63. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 39 in which the sole active component is 1-hydroxy-4-methyl-6-(4-(4-chlorophenoxy)phenoxy)methyl)-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the foregoing.

64. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 39 in which the composition further comprises at least one additional surfactant chosen from anionic, cationic, nonionic, and amphoteric surfactants.

65. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 38, in which the sole active component is a pharmaceutically acceptable salt of a 1-hydroxy-2-pyridone of formula I, and in which the composition further comprises lactic acid to adjust the pH of the composition to the pH ranging from about 4.5 to about 6.5.

66. (Previously Presented) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 39, in which the composition further comprises lactic acid to adjust the pH of the composition.

Claim 67 (Canceled)